SynthesisFrontiers in oncology2025
Comparative safety and efficacy of tislelizumab-based regimens versus chemotherapy in lung cancer: a systematic review and meta-analysis.
Synthesis in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Lung cancer is the leading cause of cancer-related mortality worldwide, with its burden expected to rise significantly by 2025. Despite therapeutic advances, survival rates remain low, and comorbidities further complicate management. Economic projections indicate lung cancer will account for the highest share of cancer-related costs through 2050. Objectives: To evaluate the safety and efficacy of Tislelizumab with or without chemotherapy versus chemotherapy alone in lung cancer by synthesizing available evidence through meta-analysis. Methodology: This meta-analysis followed PRISMA guidelines and was registered in PROSPERO. A systematic search of PubMed, Embase, Scopus, Cochrane Library, ScienceDirect, and ClinicalTrials.gov was conducted for RCTs comparing Tislelizumab-based regimens to chemotherapy in lung cancer (up to February 2025). Key outcomes included PFS, OS, ORR, DCR, and AEs. Bias was assessed using the Cochrane tool, and data were analyzed with random-effects models, incorporating subgroup and sensitivity analyses. Publication bias was assessed via funnel plots and Egger's test. Results: A total of six studies involving 2,148 patients were included in the meta-analysis. Tislelizumab-based regimens showed significant improvements in PFS (HR = 0.62, p < 0.0001) and OS (HR = 0.69, p < 0.0001) compared to chemotherapy alone. The ORR (RR = 1.49, p= 0.0001) and DCR (RR = 1.49, p= 0.0010) were significantly higher in the Tislelizumab group. The Tislelizumab group significantly reduced all-cause mortality (RR = 0.89, p = 0.0003). No significant differences were found in AEs (RR = 1.00, p= 0.75), except for ALT and AST elevations (RR = 1.36; 95% CI, 1.13-1.64) and (RR = 1.77; 95% CI, 1.17-2.67), respectively. Conclusions: Tislelizumab-based regimens offer significant benefits over chemotherapy in lung cancer, with improved PFS, OS, and ORR. It significantly reduced all-cause mortality; however, the observed increase in ALT and AST underscores the need for vigilant liver function monitoring. Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD42025641055, Identifier CRD42025641055.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.